Barrington Research Reiterates “Outperform” Rating for LeMaitre Vascular (NASDAQ:LMAT)

Barrington Research restated their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report published on Thursday, Briefing.com Automated Import reports. The brokerage currently has a $37.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $32.00.

Other analysts also recently issued reports about the company. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a buy rating to a hold rating in a research note on Tuesday, May 7th. ValuEngine raised Zumiez from a sell rating to a hold rating in a research note on Monday, July 22nd. BidaskClub downgraded Westport Fuel Systems from a buy rating to a hold rating in a research note on Friday, July 19th. Finally, First Analysis raised LeMaitre Vascular from a neutral rating to an outperform rating and increased their price objective for the stock from $29.00 to $37.00 in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $35.33.

Shares of LeMaitre Vascular stock opened at $32.60 on Thursday. The stock has a market capitalization of $641.27 million, a P/E ratio of 38.81, a PEG ratio of 3.20 and a beta of 1.14. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $38.99. The business has a 50 day moving average of $28.33.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, July 24th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the consensus estimate of $0.21 by $0.02. The firm had revenue of $29.48 million during the quarter, compared to the consensus estimate of $28.90 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 16.72%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. On average, equities analysts forecast that LeMaitre Vascular will post 0.86 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 5th. Stockholders of record on Wednesday, August 21st will be issued a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 1.04%. The ex-dividend date is Tuesday, August 20th. LeMaitre Vascular’s dividend payout ratio is presently 40.48%.

In other news, Chairman George W. Lemaitre sold 66,037 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $34.45, for a total value of $2,274,974.65. Following the completion of the transaction, the chairman now directly owns 3,171,124 shares of the company’s stock, valued at $109,245,221.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 19.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in LMAT. BNP Paribas Arbitrage SA grew its holdings in shares of LeMaitre Vascular by 66,640.0% in the first quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock valued at $103,000 after acquiring an additional 3,332 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new position in shares of LeMaitre Vascular in the fourth quarter valued at approximately $106,000. Metropolitan Life Insurance Co. NY grew its holdings in shares of LeMaitre Vascular by 373.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 4,441 shares in the last quarter. BB&T Corp bought a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $203,000. Finally, Globeflex Capital L P grew its holdings in shares of LeMaitre Vascular by 26.5% in the first quarter. Globeflex Capital L P now owns 6,578 shares of the medical instruments supplier’s stock valued at $204,000 after acquiring an additional 1,378 shares in the last quarter. 77.16% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: What is a balanced fund?

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.